NanoAssemblr™ Commercial Manufacturing System

Overview

The NanoAssemblr™ Commercial Manufacturing System is a fully automated, GMP-compliant platform engineered for the scalable, reproducible production of lipid nanoparticle (LNP) formulations—particularly for mRNA, saRNA, and other nucleic acid therapeutics. Built upon Cytiva’s NxGen™ microfluidic mixing technology, the system operates on the principle of controlled turbulent mixing within precision-engineered annular microchannels, enabling rapid, homogeneous nanoprecipitation under defined hydrodynamic conditions. Unlike passive diffusion-based methods, this active mixing architecture ensures consistent residence time distribution, minimized shear degradation, and tight control over critical process parameters (CPPs) such as flow rate ratio, total flow rate, and mixing Reynolds number—directly impacting critical quality attributes (CQAs) including particle size, polydispersity index (PDI), encapsulation efficiency, and batch-to-batch reproducibility. Designed specifically for clinical- and commercial-scale manufacturing, the system bridges the gap between early-stage development (e.g., NanoAssemblr™ Ignite+™ and NxGen™ 500) and full-scale GMP operations without re-optimization of formulation or process.

Key Features

• Fully automated workflow with guided sequence execution for priming, calibration, formulation preparation, and inline dilution—reducing manual intervention and operator-dependent variability.
• Real-time closed-loop monitoring and control of pump speeds and volumetric flow rates via integrated Coriolis flow meters and pressure sensors.
• Disposable flow path kits validated for single-use operation, eliminating the need for cleaning-in-place (CIP) or sterilization-in-place (SIP) procedures and minimizing cleanroom downtime between campaigns.
• NxGen™ mixing technology featuring proprietary annular microchannel geometry—delivering laminar-to-turbulent transition at low Reynolds numbers for highly repeatable mixing kinetics across scales.
• ATEX and IECEx certification for use in Zone 1 hazardous environments, enabling safe handling of flammable organic solvents (e.g., ethanol, isopropanol) commonly employed in LNP formulation.
• GMP-ready architecture compliant with FDA 21 CFR Part 11 requirements, supporting electronic signatures, audit trails, and role-based user access control.

Sample Compatibility & Compliance

The system accommodates a broad range of nucleic acid payloads—including mRNA, self-amplifying RNA (saRNA), siRNA, and DNA—as well as diverse lipid compositions (ionizable, helper, cholesterol, PEG-lipids). All disposable components are manufactured from USP Class VI-certified, animal-component-free, gamma-irradiated (25.0–45.0 kGy) materials and assembled in ISO Class 7 cleanrooms. The platform supports compliance with ICH Q5A(R2), Q5B, Q5D, and Q8(R3) guidelines, and its operational design aligns with EU Annex 1 (2022) requirements for sterile manufacturing of advanced therapy medicinal products (ATMPs). Process validation documentation packages—including IQ/OQ/PQ protocols, risk assessments (FMEA), and CPP/CQA correlation matrices—are available to support regulatory submissions.

Software & Data Management

The embedded control software provides intuitive graphical interface navigation, real-time parameter visualization, and configurable alarm thresholds. All system events—including method execution, sensor readings, user actions, and error logs—are recorded with time-stamped, immutable audit trails meeting ALCOA+ principles. Electronic batch records (EBRs) are generated per run and exportable in PDF/A-2 or CSV formats. Software architecture conforms to FDA 21 CFR Part 11 and EU Annex 11 standards, incorporating electronic signature workflows, data integrity safeguards, and secure database encryption (AES-256). Optional integration with MES/LIMS systems is supported via OPC UA and RESTful API interfaces.

Applications

• Commercial-scale GMP manufacturing of LNP-formulated vaccines (e.g., saRNA-LNP against SARS-CoV-2, influenza, RSV).
• Process transfer and tech transfer from lab-scale (NxGen™ Benchtop) to clinical (Ignite+™) and commercial platforms—maintaining identical CQAs across scales (size: 70–100 nm; PDI 95%).
• Development of stable, high-potency LNPs for oncology therapeutics, gene editing tools (e.g., CRISPR-Cas ribonucleoprotein complexes), and rare disease applications.
• Supporting Phase III clinical trials and commercial launch through robust, scalable, and auditable manufacturing processes.
• Enabling rapid response pandemic preparedness via flexible, reconfigurable production lines capable of switching between multiple LNP formulations within hours.

FAQ

What regulatory standards does the NanoAssemblr™ Commercial Manufacturing System support?
The system is designed to meet FDA 21 CFR Part 11, EU Annex 11, ICH Q5/Q8/Q9/Q10, and ISO 13485 requirements. Full validation documentation packages are provided for IQ/OQ/PQ and process characterization studies.
Can the system be integrated into an existing manufacturing execution system (MES)?
Yes—via standard OPC UA and RESTful API protocols, enabling bidirectional data exchange with enterprise-level MES, LIMS, and SCADA platforms.
How long does it take to install and qualify a disposable flow path kit?
Installation and mechanical qualification can be completed in ≤60 minutes by trained personnel; no re-calibration is required between kits of the same configuration.
Is the NxGen™ mixing technology scalable from benchtop to commercial scale?
Yes—NxGen™ maintains identical mixing physics and CPP mapping across all platforms (Benchtop → Ignite+™ → Commercial), enabling direct process transfer without re-optimization of formulation or operating parameters.
What solvent compatibility does the system offer for LNP formulation?
The system supports common LNP co-solvent systems including ethanol/water and isopropanol/water mixtures, with ATEX/IECEx certification ensuring intrinsic safety during solvent handling.